High Free Cash Flow Stocks
BCRX is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
BIOCRYST PHARMACEUTICALS INC (BCRX) Stock Price & Overview
NASDAQ:BCRX • US09058V1035
Current stock price
9.02 USD
-0.36 (-3.84%)
At close:
9.0509 USD
+0.03 (+0.34%)
After Hours:
The current stock price of BCRX is 9.02 USD. Today BCRX is down by -3.84%. In the past month the price increased by 6.12%. In the past year, price increased by 32.06%.
BCRX Key Statistics
52-Week Range6 - 11.31
Current BCRX stock price positioned within its 52-week range.
1-Month Range8.15 - 10.32
Current BCRX stock price positioned within its 1-month range.
- Market Cap
- 2.262B
- P/E
- 82.00
- Fwd P/E
- 22.94
- EPS (TTM)
- 0.11
- Dividend Yield
- N/A
BCRX Stock Performance
Today
-3.84%
1 Week
-5.65%
1 Month
+6.12%
3 Months
+20.27%
Longer-term
6 Months +26.15%
1 Year +32.06%
2 Years +118.40%
3 Years +18.53%
5 Years -22.48%
10 Years +176.69%
BCRX Stock Chart
BCRX Stock Screens
BCRX currently appears in the following ChartMill screener lists.
Fastest Growing Stocks
BCRX is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
Revenue Growth Leaders
BCRX is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
Strong Momentum Stocks
BCRX is part of our Strong Momentum Stocks screen, indicating it has an already in confirmed uptrend.
BCRX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to BCRX. When comparing the yearly performance of all stocks, BCRX is one of the better performing stocks in the market, outperforming 80.4% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
BCRX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to BCRX. BCRX has only an average score on both its financial health and profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BCRX Earnings
On February 26, 2026 BCRX reported an EPS of 0.01 and a revenue of 162.57M. The company missed EPS expectations (-74.12% surprise) and beat revenue expectations (6.52% surprise).
Next Earnings DateMay 4, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported$0.01
Revenue Reported162.575M
EPS Surprise -74.12%
Revenue Surprise 6.52%
BCRX Forecast & Estimates
16 analysts have analysed BCRX and the average price target is 21.73 USD. This implies a price increase of 140.86% is expected in the next year compared to the current price of 9.02.
For the next year, analysts expect an EPS growth of 257.46% and a revenue growth 5.3% for BCRX
Analysts
Analysts85
Price Target21.73 (140.91%)
EPS Next Y257.46%
Revenue Next Year5.3%
BCRX Groups
Sector & Classification
BCRX Financial Highlights
Over the last trailing twelve months BCRX reported a non-GAAP Earnings per Share(EPS) of 0.11. The EPS increased by 125.58% compared to the year before.
Income Statements
Revenue(TTM)874.84M
Net Income(TTM)263.86M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 30.16% | ||
| ROA | 51.32% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%107.69%
Sales Q2Q%23.6%
EPS 1Y (TTM)125.58%
Revenue 1Y (TTM)94.1%
BCRX Ownership
Ownership
Inst Owners83.2%
Shares250.80M
Float242.61M
Ins Owners0.79%
Short Float %15.45%
Short Ratio6.78
BCRX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BCRX
Company Profile
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is headquartered in Durham, North Carolina and currently employs 435 full-time employees. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. The company has also obtained an early-stage program for atopic dermatitis, STAR0310.
Company Info
IPO: 1994-03-04
BIOCRYST PHARMACEUTICALS INC
4505 Emperor Blvd Ste 200
Durham NORTH CAROLINA 27703 US
CEO: Jon P. Stonehouse
Employees: 435
Phone: 13026365400
BIOCRYST PHARMACEUTICALS INC / BCRX FAQ
Can you describe the business of BIOCRYST PHARMACEUTICALS INC?
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is headquartered in Durham, North Carolina and currently employs 435 full-time employees. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. The company has also obtained an early-stage program for atopic dermatitis, STAR0310.
What is the current price of BCRX stock?
The current stock price of BCRX is 9.02 USD. The price decreased by -3.84% in the last trading session.
Does BCRX stock pay dividends?
BCRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of BCRX stock?
BCRX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
How is the valuation of BIOCRYST PHARMACEUTICALS INC (BCRX) based on its PE ratio?
The PE ratio for BIOCRYST PHARMACEUTICALS INC (BCRX) is 82. This is based on the reported non-GAAP earnings per share of 0.11 and the current share price of 9.02 USD.
What is the next earnings date for BCRX stock?
BIOCRYST PHARMACEUTICALS INC (BCRX) will report earnings on 2026-05-04, before the market open.
Who owns BIOCRYST PHARMACEUTICALS INC?
You can find the ownership structure of BIOCRYST PHARMACEUTICALS INC (BCRX) on the Ownership tab.